OUR MISSION:
Enhancing survival and quality of life for people living with GIST through patient-powered research, education and empowerment, and global advocacy efforts.
These are our Core Values:
PATIENT
Leverage patient perspective to drive innovative solutions in cancer research.
POWERED
Educate and empower patients to take a larger role in their care.
SCIENCE
Accelerate research outcomes through collaborative efforts.
FOR LIFE
Increase access to effective treatments worldwide.
Real World Evidence In Action
PROJECT InterGR
Traditional models for cancer research have resulted in many breakthrough treatments for patients, but it is not enough. Project InterGR, the LRG’s approach to research through real world evidence, relies on timely, accurate data from the patient’s perspective, with patient survival as the primary objective.
RECENT LRG DATA
Did you know that GIST is actually a family of cancers? Learn more about the science of GIST.
Update your Patient Registry Information.
Join The Life Raft Group.
Available GIST clinical trials.
Search our database of GIST Specialists.
Dr. Monica Anderson
Diagnosed in 2012 with Adult GIST.
Marc Wasserman
Diagnosed in 2006 with Adult GIST.
Bella Rocco
Diagnosed in 2009 with Pediatric
(SDH-Deficient) GIST.
HELP US SAVE LIVES
The Life Raft Group is a community and it is up to all of us to make a difference. There are many ways to help, we always need patient tissue and data in our registry. Volunteering your time or making a monetary donation also helps us drive research forward and save lives.
Treatment Responses in SDH-deficient GIST – LRG Science
PDF is available of LRG Science here. Treatment Responses in SDH-deficient GIST Patient-reported Treatment Responses in Known/Likely SDH-deficient GISTS: An Analysis of The Life Raft Group Observational Registry Authored by LRG [...]
LRG Webcast: Optimizing GIST Treatment – Hebrew Subtitles
This webcast was originally recorded May 21, 2019. Follow this link for webcast with Hebrew Subtitles. Listen to the webcast [...]
Rozlytrek™ (entrectnib) by Approved by FDA
The FDA granted the approval of Rozlytrek™ (entrectnib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC), [...]
LRG Webcast Series: When to Consider Surgery
When to Consider Surgery This webcast will address the issues surrounding the decision to have an operation. Most GIST patients will [...]
Deciphera Releases Positive Trial Results for Ripretinib
Deciphera Pharmaceuticals has released positive results from their INVICTUS Phase 3 Clinical Study of Ripretinib in patients with GIST. They have [...]
Treatment Responses in SDH-deficient GIST – LRG Science
PDF is available of LRG Science here. Treatment Responses in SDH-deficient GIST Patient-reported Treatment Responses in Known/Likely SDH-deficient [...]
LRG Releases Annual Report for 2018
In 2018, The Life Raft Group continued its dedication to patients with GIST, working diligently to enhance survival and quality of [...]
Blueprint Medicines Announces Next Step for Avaprinitib
Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and [...]
LRG Volunteer Wins Prestigious Award
David Epstein, LRG Pro Bono HR Consultant, Honored as a Leader The Life Raft Group is fortunate to have many volunteers [...]
Patient of the Month for July: Robert Little
As a part of our Faces of Courage series, we are featuring a patient story each month. Each one of our [...]
Creating Your Personal Cancer Survival Plan
This presentation is best viewed with the "Personal Cancer Survival Plan - 10 Steps to Surviving Cancer Guide" [...]
